UTHR Overview

United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder product.

Wall Street analysts forecast UTHR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for UTHR is534.50 USD with a low forecast of 423.00 USD and a high forecast of 645.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

United Therapeutics Corp revenue for the last quarter amounts to 781.50M USD, decreased -1.62

United Therapeutics Corp. EPS for the last quarter amounts to 5.82 USD, decreased -12.22

United Therapeutics Corp (UTHR) has 1400 emplpoyees as of May 11 2026.

Today UTHR has the market capitalization of 23.98B USD.